SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?

To: Sam Citron who wrote (1648)2/23/2000 10:42:00 AM
From: Charlie Smith  Read Replies (2) | Respond to of 1754
 
Sam:

Most telling remark by Logan on conference call this AM:

"None of our (current -ex BOL) competitors are profitable"

Logan is scorching the earth with this announcement. It's designed to make the above situation permanent. VISX certainly absorbs a huge hit to P&L, but the screws just tightened considerably on Nidek, Summit, Chiron, et al. How deep are their pockets? How long can they stay in the game? BOL may license at the new low level, and these two could divide the market between them. If BOL decides to fight or buy up weaker players, then VISX could be in bigger trouble.

Charlie



To: Sam Citron who wrote (1648)2/23/2000 10:29:00 PM
From: Tom Hua  Read Replies (1) | Respond to of 1754
 
Sam, hard for me to see more downside from here. I picked up Mar 20 calls for 1 3/16 in anticipation of major movement (up or down) on 3/7. Since I feel downside is very limited, I should have bought the stock too. Maybe tomorrow.

Regards,

Tom


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News